<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29489644</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>e0011</StartPage>
          <MedlinePgn>e0011</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0011</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000010011</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Paraneoplastic limbic encephalitis (PLE) is one of the most common causes of neurologic paraneoplastic syndromes, with unclear pathogenesis. While several reports published in the last decades showed the occurrence of PLE in a variety of cancers, only a few cases have been associated with colon cancer.</AbstractText>
          <AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">In February 2017, a 54-year-old man with clinical history of radically resected colon cancer started first line chemotherapy with FOLFOXIRI plus bevacizumab, after radiological diagnosis of multiple liver and bone metastases. During the third cycle of treatment, the patient developed psychomotor agitation and hallucinations followed by severe consciousness level reduction and cognitive impairment.</AbstractText>
          <AbstractText Label="DIAGNOSES" NlmCategory="METHODS">Magnetic resonance imaging showed hyperintense signals in both hippocampal areas, insula and right cingulate gyrus on fluid attenuated inversion recovery, diffusion weighted imaging, and T2-weighted images, highly suggestive of limbic encephalitis. Other causes (brain metastases, toxicity of chemotherapeutic agents, and infections) were excluded.</AbstractText>
          <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Empirical immunosuppressive treatment (high-dose immunoglobulins and corticosteroids) was administered and chemotherapy was resumed.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">A slowly progressive improvement in neurological condition has been observed, even though radiological signs of limbic encephalitis are still evident.</AbstractText>
          <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">The present case highlights the complex diagnostic process of PLE, and the lack of a standard treatment. Moreover, the absence of correlation between PLE and tumor progression or tumor burden, and the opportunity of treating underlying neoplasm is discussed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Attademo</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine and Surgery Department of Neurosciences, Reproductive Sciences and Odontostomatology Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Falco</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosanova</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Esposito</LastName>
            <ForeName>Marcello</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mazio</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foschini</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santaniello</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiore</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matano</LastName>
            <ForeName>Elide</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manganelli</LastName>
            <ForeName>Fiore</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carlomagno</LastName>
            <ForeName>Chiara</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29489644</ArticleId>
        <ArticleId IdType="pmc">PMC5851735</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000010011</ArticleId>
        <ArticleId IdType="pii">00005792-201803020-00005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Giometto B, Grisold W, Vitaliani R, et al. 
For the PNS Euronetwork. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol
2010;67:330–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20212230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB, Posner JB.
Paraneoplastic syndromes involving the nervous system. N Engl J Med
2003;349:1543–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al. 
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain
2000;123(Pt 7):1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sio TT, Paredes M, Uzair C.
Neurological manifestation of colonic adenocarcinoma. Rare Tumors
2012;4:e32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401160</ArticleId>
            <ArticleId IdType="pubmed">22826789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janati A, Gray RP, Souheaver GT.
A mental syndrome associated with colonic carcinoma: limbic encephalitis?
Psychosomatics
1987;28:48–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3562763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adam VN, Budinčević H, Mršić V, et al. 
Paraneoplastic limbic encephalitis in a patient with adenocarcinoma of the colon: a case report. A J Clin Anesth
2013;25:491–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23965208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riva M, Brioschi AM, Marazzi R, et al. 
Immunological and endocrinological abnormalities in paraneoplastic disorders with involvement of the autonomic nervous system. Ital J Neurol Sci
1997;18:157–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9241563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukamoto T, Mochizuki R, Mochizuki H, et al. 
Paraneoplastic cerebellar degeneration and limbic encephalitis in a patient with adenocarcinoma of the colon. J Neurol Neurosurg Psychiatry
1993;56:713–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC489629</ArticleId>
            <ArticleId IdType="pubmed">8509793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Marco S, Squilloni E, Vigna L, et al. 
Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann Oncol
2004;15:1147–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15205214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gluske P, Ozcan C.
Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med
2006;354:980–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16514715</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
